Trial · NCT00209131
Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy
NCT00209131, Not applicable, Terminated, Emory University; results first posted 2012-07-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy. Trials, record NCT00209131. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00209131
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy
- NCT number
- NCT00209131
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 24 participants, actual
- Lead sponsor
- Emory University
- Conditions
- Urolithiasis
- Interventions
- Flomax, Sugar pill
- First posted
- 2005-09-21
- Last updated
- 2013-10-28
- Results first posted
- 2012-07-09
- Limitations and caveats
Study was terminated due to turnovers of personnel to assist with recruitment and execution of the study.Recruitment was strained and patients recruited could not be followed up in a timely fashion to adhere to protocol. Thus, no data was generated.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to Passage of Stone Fragments | 2 weeks and 3 months | Time to passage of stone fragments following shock wave lithotripsy as documented by patient diaries and follow-up radiographic imaging. |
| Secondary | Medical Evaluation | 2 weeks and 3 months | Evaluation of pain assessments, lower urinary tract symptoms, side effects of study medication and need for hospitalizations and additional endoscopic procedures. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Time to Passage of Stone Fragments | 2 weeks and 3 months | No analysis was conducted. | ||
| SECONDARY | Medical Evaluation | 2 weeks and 3 months |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Flomax | 15 | |
| Overall Study | STARTED | Sugar Pill | 11 | |
| Overall Study | COMPLETED | Flomax | 0 | |
| Overall Study | COMPLETED | Sugar Pill | 0 | |
| Overall Study | NOT COMPLETED | Flomax | 15 | |
| Overall Study | NOT COMPLETED | Sugar Pill | 11 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Flomax | ||
| Total, all-cause mortality | Sugar Pill | ||
| Total, other adverse events | Flomax | 0 | 0 |
| Total, other adverse events | Sugar Pill | 0 | 0 |
| Total, serious adverse events | Flomax | 0 | 0 |
| Total, serious adverse events | Sugar Pill | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00209131
GET https://conductscience.org/api/trials/v1/NCT00209131/registered